$17.32
0.41% day before yesterday
NYSE, Jan 02, 10:11 pm CET
ISIN
US49177J1025
Symbol
KVUE

Kenvue Stock price

$17.32
+0.46 2.73% 1M
-3.58 17.13% 6M
+0.07 0.41% YTD
-3.96 18.61% 1Y
-9.58 35.61% 3Y
-9.58 35.61% 5Y
-9.58 35.61% 10Y
-9.58 35.61% 20Y
NYSE, Closing price Fri, Jan 02 2026
+0.07 0.41%
ISIN
US49177J1025
Symbol
KVUE
Index

New AI Insights on Kenvue Insights AI Insights on Kenvue

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$33.2b
Enterprise Value
$41.0b
Net debt
$7.8b
Cash
$1.1b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
23.4 | 16.5
P/S
2.2 | 2.2
EV/Sales
2.7 | 2.7
EV/FCF
25.0
P/B
3.1
Dividends
DPS
$0.83
Yield 1Y | 5Y
4.8% | 1.9%
Growth 1Y | 5Y
1.9% | -
Payout 1Y | 3Y
150.0% | 47.6%
Increased
3 Years
Financials (TTM | estimate)
Revenue
$15.0b | $15.3b
EBITDA
$3.2b | $3.4b
EBIT
$2.7b | $3.0b
Net Income
$1.4b | $2.0b
Free Cash Flow
$1.6b
Growth (TTM | estimate)
Revenue
-2.9% | -0.8%
EBITDA
-4.6% | -4.3%
EBIT
-2.9% | 2.7%
Net Income
34.7% | 95.7%
Free Cash Flow
17.0%
Margin (TTM | estimate)
Gross
58.5%
EBITDA
21.6% | 22.2%
EBIT
17.9%
Net
9.6% | 13.1%
Free Cash Flow
10.9%
Financial Health
Equity Ratio
37.8%
Return on Equity
10.7%
ROCE
12.7%
ROIC
8.5%
Debt/Equity
0.8
More
EPS
$0.7
FCF per Share
$0.9
Short interest
3.7%
Employees
22k
Rev per Employee
$700.0k
Show more

Is Kenvue a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Kenvue Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Kenvue forecast:

7x Buy
33%
13x Hold
62%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a Kenvue forecast:

Buy
33%
Hold
62%
Sell
5%

Financial data from Kenvue

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
15,006 15,006
3% 3%
100%
- Direct Costs 6,227 6,227
4% 4%
41%
8,779 8,779
2% 2%
59%
- Selling and Administrative Expenses 5,678 5,678
2% 2%
38%
- Research and Development Expense 390 390
10% 10%
3%
3,248 3,248
5% 5%
22%
- Depreciation and Amortization 569 569
12% 12%
4%
EBIT (Operating Income) EBIT 2,679 2,679
3% 3%
18%
Net Profit 1,433 1,433
35% 35%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Kenvue directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kenvue Stock News

Neutral
MarketBeat
2 days ago
Insider buying can be one of the cleanest “follow-the-money” signals in the market. Over the past month or so, three names have stood out for $100 million-plus buying tied to prominent funds and well-known professional investors.
Positive
Seeking Alpha
3 days ago
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Neutral
Seeking Alpha
6 days ago
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.
More Kenvue News

Company Profile

Kenvue, Inc. engages in the provision of healthcare products services. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment includes oral care, baby care, women’s health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Head office United States
CEO Thibaut Mongon
Employees 22,000
Website www.kenvue.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today